Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Advances in preclinical approaches to Chagas disease drug discovery.

Villalta F, Rachakonda G.

Expert Opin Drug Discov. 2019 Nov;14(11):1161-1174. doi: 10.1080/17460441.2019.1652593. Epub 2019 Aug 14.

PMID:
31411084
2.

A Novel Role of Prolidase in Cocaine-Mediated Breach in the Barrier of Brain Microvascular Endothelial Cells.

Ysrayl BB, Balasubramaniam M, Albert I, Villalta F, Pandhare J, Dash C.

Sci Rep. 2019 Feb 22;9(1):2567. doi: 10.1038/s41598-018-37495-6.

3.

Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.

Guedes-da-Silva FH, Batista DDGJ, Da Silva CF, Pavão BP, Batista MM, Moreira OC, Souza LRQ, Britto C, Rachakonda G, Villalta F, Lepesheva GI, Soeiro MNC.

ACS Infect Dis. 2019 Mar 8;5(3):365-371. doi: 10.1021/acsinfecdis.8b00253. Epub 2019 Jan 23.

PMID:
30625275
4.

Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.

Friggeri L, Hargrove TY, Rachakonda G, Blobaum AL, Fisher P, de Oliveira GM, da Silva CF, Soeiro MNC, Nes WD, Lindsley CW, Villalta F, Guengerich FP, Lepesheva GI.

J Med Chem. 2018 Dec 13;61(23):10910-10921. doi: 10.1021/acs.jmedchem.8b01671. Epub 2018 Nov 30.

PMID:
30451500
5.

Phospho-proteomic analysis of primary human colon epithelial cells during the early Trypanosoma cruzi infection phase.

Suman S, Rachakonda G, Mandape SN, Sakhare SS, Villalta F, Pratap S, Lima MF, Nde PN.

PLoS Negl Trop Dis. 2018 Sep 17;12(9):e0006792. doi: 10.1371/journal.pntd.0006792. eCollection 2018 Sep.

6.

Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic Analysis.

Friggeri L, Hargrove TY, Wawrzak Z, Blobaum AL, Rachakonda G, Lindsley CW, Villalta F, Nes WD, Botta M, Guengerich FP, Lepesheva GI.

J Med Chem. 2018 Jul 12;61(13):5679-5691. doi: 10.1021/acs.jmedchem.8b00641. Epub 2018 Jun 25.

7.

Poly (ADP-Ribose) Polymerase-1 (PARP-1) Induction by Cocaine Is Post-Transcriptionally Regulated by miR-125b.

Dash S, Balasubramaniam M, Rana T, Godino A, Peck EG, Goodwin JS, Villalta F, Calipari ES, Nestler EJ, Dash C, Pandhare J.

eNeuro. 2017 Aug 18;4(4). pii: ENEURO.0089-17.2017. doi: 10.1523/ENEURO.0089-17.2017. eCollection 2017 Jul-Aug. Erratum in: eNeuro. 2018 Apr 18;5(2):.

8.

Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity.

Hargrove TY, Garvey EP, Hoekstra WJ, Yates CM, Wawrzak Z, Rachakonda G, Villalta F, Lepesheva GI.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00570-17. doi: 10.1128/AAC.00570-17. Print 2017 Jul.

9.

Novel Catalytically-Inactive PII Metalloproteinases from a Viperid Snake Venom with Substitutions in the Canonical Zinc-Binding Motif.

Camacho E, Sanz L, Escalante T, Pérez A, Villalta F, Lomonte B, Neves-Ferreira AG, Feoli A, Calvete JJ, Gutiérrez JM, Rucavado A.

Toxins (Basel). 2016 Oct 12;8(10). pii: E292.

10.

Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease.

Matthews QL, Farrow AL, Rachakonda G, Gu L, Nde P, Krendelchtchikov A, Pratap S, Sakhare SS, Sabbaj S, Lima MF, Villalta F.

Pathog Immun. 2016 Fall-Winter;1(2):214-233.

11.

Early Regulation of Profibrotic Genes in Primary Human Cardiac Myocytes by Trypanosoma cruzi.

Udoko AN, Johnson CA, Dykan A, Rachakonda G, Villalta F, Mandape SN, Lima MF, Pratap S, Nde PN.

PLoS Negl Trop Dis. 2016 Jan 15;10(1):e0003747. doi: 10.1371/journal.pntd.0003747. eCollection 2016 Jan.

12.

Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.

Dotson D, Woodruff EA, Villalta F, Dong X.

J Biol Chem. 2016 Feb 19;291(8):4236-46. doi: 10.1074/jbc.M115.708123. Epub 2016 Jan 7.

13.

Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.

Hoekstra WJ, Hargrove TY, Wawrzak Z, da Gama Jaen Batista D, da Silva CF, Nefertiti AS, Rachakonda G, Schotzinger RJ, Villalta F, Soeiro Mde N, Lepesheva GI.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1058-66. doi: 10.1128/AAC.02287-15. Print 2016 Feb.

14.

Impact of cocaine abuse on HIV pathogenesis.

Dash S, Balasubramaniam M, Villalta F, Dash C, Pandhare J.

Front Microbiol. 2015 Oct 20;6:1111. doi: 10.3389/fmicb.2015.01111. eCollection 2015. Review.

15.

A Novel Role of Proline Oxidase in HIV-1 Envelope Glycoprotein-induced Neuronal Autophagy.

Pandhare J, Dash S, Jones B, Villalta F, Dash C.

J Biol Chem. 2015 Oct 16;290(42):25439-51. doi: 10.1074/jbc.M115.652776. Epub 2015 Sep 1.

16.

VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.

Lepesheva GI, Hargrove TY, Rachakonda G, Wawrzak Z, Pomel S, Cojean S, Nde PN, Nes WD, Locuson CW, Calcutt MW, Waterman MR, Daniels JS, Loiseau PM, Villalta F.

J Infect Dis. 2015 Nov 1;212(9):1439-48. doi: 10.1093/infdis/jiv228. Epub 2015 Apr 15.

17.

Discovery of an ergosterol-signaling factor that regulates Trypanosoma brucei growth.

Haubrich BA, Singha UK, Miller MB, Nes CR, Anyatonwu H, Lecordier L, Patkar P, Leaver DJ, Villalta F, Vanhollebeke B, Chaudhuri M, Nes WD.

J Lipid Res. 2015 Feb;56(2):331-41. doi: 10.1194/jlr.M054643. Epub 2014 Nov 25.

18.

Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.

Farrow AL, Rachakonda G, Gu L, Krendelchtchikova V, Nde PN, Pratap S, Lima MF, Villalta F, Matthews QL.

PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3089. doi: 10.1371/journal.pntd.0003089. eCollection 2014 Aug.

19.

Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition.

Friggeri L, Hargrove TY, Rachakonda G, Williams AD, Wawrzak Z, Di Santo R, De Vita D, Waterman MR, Tortorella S, Villalta F, Lepesheva GI.

J Med Chem. 2014 Aug 14;57(15):6704-17. doi: 10.1021/jm500739f. Epub 2014 Jul 29.

20.

Cocaine enhances HIV-1-induced CD4(+) T-cell apoptosis: implications in disease progression in cocaine-abusing HIV-1 patients.

Pandhare J, Addai AB, Mantri CK, Hager C, Smith RM, Barnett L, Villalta F, Kalams SA, Dash C.

Am J Pathol. 2014 Apr;184(4):927-936. doi: 10.1016/j.ajpath.2013.12.004. Epub 2014 Jan 31.

21.

Cellular response to Trypanosoma cruzi infection induces secretion of defensin α-1, which damages the flagellum, neutralizes trypanosome motility, and inhibits infection.

Johnson CA, Rachakonda G, Kleshchenko YY, Nde PN, Madison MN, Pratap S, Cardenas TC, Taylor C, Lima MF, Villalta F.

Infect Immun. 2013 Nov;81(11):4139-48. doi: 10.1128/IAI.01459-12. Epub 2013 Aug 26.

22.

VNI cures acute and chronic experimental Chagas disease.

Villalta F, Dobish MC, Nde PN, Kleshchenko YY, Hargrove TY, Johnson CA, Waterman MR, Johnston JN, Lepesheva GI.

J Infect Dis. 2013 Aug 1;208(3):504-11. doi: 10.1093/infdis/jit042. Epub 2013 Jan 31.

23.

Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease.

Dobish MC, Villalta F, Waterman MR, Lepesheva GI, Johnston JN.

Org Lett. 2012 Dec 21;14(24):6322-5. doi: 10.1021/ol303092v. Epub 2012 Dec 7.

24.

Regulation and use of the extracellular matrix by Trypanosoma cruzi during early infection.

Nde PN, Lima MF, Johnson CA, Pratap S, Villalta F.

Front Immunol. 2012 Nov 6;3:337. doi: 10.3389/fimmu.2012.00337. eCollection 2012.

25.

Defective HIV-1 particle assembly in AP-3-deficient cells derived from patients with Hermansky-Pudlak syndrome type 2.

Liu L, Sutton J, Woodruff E, Villalta F, Spearman P, Dong X.

J Virol. 2012 Oct;86(20):11242-53. Epub 2012 Aug 8.

26.

Thrombospondin-1 interacts with Trypanosoma cruzi surface calreticulin to enhance cellular infection.

Johnson CA, Kleshchenko YY, Ikejiani AO, Udoko AN, Cardenas TC, Pratap S, Duquette MA, Lima MF, Lawler J, Villalta F, Nde PN.

PLoS One. 2012;7(7):e40614. doi: 10.1371/journal.pone.0040614. Epub 2012 Jul 11.

27.

Novel sterol metabolic network of Trypanosoma brucei procyclic and bloodstream forms.

Nes CR, Singha UK, Liu J, Ganapathy K, Villalta F, Waterman MR, Lepesheva GI, Chaudhuri M, Nes WD.

Biochem J. 2012 Apr 1;443(1):267-77. doi: 10.1042/BJ20111849.

28.

Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).

Lepesheva GI, Villalta F, Waterman MR.

Adv Parasitol. 2011;75:65-87. doi: 10.1016/B978-0-12-385863-4.00004-6. Review.

29.

Effects of human defensin-α(1)on Trypanosoma cruzi trypomastigotes in vitro.

Kleschenko YE, Karpenko LP, Villalta F.

Bull Exp Biol Med. 2010 Nov;149(6):731-3.

30.

Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi.

Lepesheva GI, Hargrove TY, Anderson S, Kleshchenko Y, Furtak V, Wawrzak Z, Villalta F, Waterman MR.

J Biol Chem. 2010 Aug 13;285(33):25582-90. doi: 10.1074/jbc.M110.133215. Epub 2010 Jun 8.

31.

Gene network analysis during early infection of human coronary artery smooth muscle cells by Trypanosoma cruzi and Its gp83 ligand.

Nde PN, Johnson CA, Pratap S, Cardenas TC, Kleshchenko YY, Furtak VA, Simmons KJ, Lima MF, Villalta F.

Chem Biodivers. 2010 May;7(5):1051-64. doi: 10.1002/cbdv.200900320.

32.

REGULATION of the EXTRACELLULAR MATRIX INTERACTOME by Trypanosoma cruzi.

Cardenas TC, Johnson CA, Pratap S, Nde PN, Furtak V, Kleshchenko YY, Lima MF, Villalta F.

Open Parasitol J. 2010;4:72-76.

33.

Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections.

Lepesheva GI, Park HW, Hargrove TY, Vanhollebeke B, Wawrzak Z, Harp JM, Sundaramoorthy M, Nes WD, Pays E, Chaudhuri M, Villalta F, Waterman MR.

J Biol Chem. 2010 Jan 15;285(3):1773-80. doi: 10.1074/jbc.M109.067470. Epub 2009 Nov 18.

34.

Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase.

Konkle ME, Hargrove TY, Kleshchenko YY, von Kries JP, Ridenour W, Uddin MJ, Caprioli RM, Marnett LJ, Nes WD, Villalta F, Waterman MR, Lepesheva GI.

J Med Chem. 2009 May 14;52(9):2846-53. doi: 10.1021/jm801643b.

35.

Perspectives on the Trypanosoma cruzi-host cell receptor interactions.

Villalta F, Scharfstein J, Ashton AW, Tyler KM, Guan F, Mukherjee S, Lima MF, Alvarez S, Weiss LM, Huang H, Machado FS, Tanowitz HB.

Parasitol Res. 2009 Jun;104(6):1251-60. doi: 10.1007/s00436-009-1383-3. Epub 2009 Mar 13. Review.

36.

CYP51: A major drug target in the cytochrome P450 superfamily.

Lepesheva GI, Hargrove TY, Kleshchenko Y, Nes WD, Villalta F, Waterman MR.

Lipids. 2008 Dec;43(12):1117-25. doi: 10.1007/s11745-008-3225-y. Epub 2008 Sep 4.

37.

Molecular analysis of early host cell infection by Trypanosoma cruzi.

Villalta F, Madison MN, Kleshchenko YY, Nde PN, Lima MF.

Front Biosci. 2008 May 1;13:3714-34. Review.

38.

Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2.

Theodore M, Kawai Y, Yang J, Kleshchenko Y, Reddy SP, Villalta F, Arinze IJ.

J Biol Chem. 2008 Apr 4;283(14):8984-94. doi: 10.1074/jbc.M709040200. Epub 2008 Jan 31. Erratum in: J Biol Chem. 2008 May 16;283(20):14176.

39.

Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth.

Lepesheva GI, Ott RD, Hargrove TY, Kleshchenko YY, Schuster I, Nes WD, Hill GC, Villalta F, Waterman MR.

Chem Biol. 2007 Nov;14(11):1283-93.

40.

Human defensin alpha-1 causes Trypanosoma cruzi membrane pore formation and induces DNA fragmentation, which leads to trypanosome destruction.

Madison MN, Kleshchenko YY, Nde PN, Simmons KJ, Lima MF, Villalta F.

Infect Immun. 2007 Oct;75(10):4780-91. Epub 2007 Jul 16.

41.

Molecular cloning of a Trypanosoma cruzi cell surface casein kinase II substrate, Tc-1, involved in cellular infection.

Augustine SA, Kleshchenko YY, Nde PN, Pratap S, Ager EA, Burns JM Jr, Lima MF, Villalta F.

Infect Immun. 2006 Jul;74(7):3922-9.

42.

Stable RNA interference of host thrombospondin-1 blocks Trypanosoma cruzi infection.

Simmons KJ, Nde PN, Kleshchenko YY, Lima MF, Villalta F.

FEBS Lett. 2006 Apr 17;580(9):2365-70.

43.

Silencing of the laminin gamma-1 gene blocks Trypanosoma cruzi infection.

Nde PN, Simmons KJ, Kleshchenko YY, Pratap S, Lima MF, Villalta F.

Infect Immun. 2006 Mar;74(3):1643-8.

44.

Human galectin-3 promotes Trypanosoma cruzi adhesion to human coronary artery smooth muscle cells.

Kleshchenko YY, Moody TN, Furtak VA, Ochieng J, Lima MF, Villalta F.

Infect Immun. 2004 Nov;72(11):6717-21.

45.
46.

Epidermal growth factor binds to a receptor on Trypanosoma cruzi amastigotes inducing signal transduction events and cell proliferation.

Ghansah TJ, Ager EC, Freeman-Junior P, Villalta F, Lima MF.

J Eukaryot Microbiol. 2002 Sep-Oct;49(5):383-90.

PMID:
12425525
47.

Trypanosoma cruzi uses a 45-kDa mucin for adhesion to mammalian cells.

Turner CW, Lima MF, Villalta F.

Biochem Biophys Res Commun. 2002 Jan 11;290(1):29-34.

PMID:
11779128
48.

A ligand that Trypanosoma cruzi uses to bind to mammalian cells to initiate infection.

Villalta F, Smith CM, Ruiz-Ruano A, Lima MF.

FEBS Lett. 2001 Sep 21;505(3):383-8.

49.
50.

Supplemental Content

Loading ...
Support Center